Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones
High-flying Cambridge upstart Magenta Therapeutic has inked an exclusive deal with a German biotech to work on drugs that might improve bone marrow transplants for patients.
Magenta is teaming up with Heidelberg Pharma, combining its stem cell platform with Heidelberg’s proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform. The duo will apply their tech across up to four targets, with the hope of developing antibody drug conjugates.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters